A rare cause of pituitary apoplexy: Cabergoline therapy

Aydin B., Aksu O., AŞCI H., KAYAN M., KORKMAZ H.

Acta Endocrinologica, vol.14, no.1, pp.113-116, 2018 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 14 Issue: 1
  • Publication Date: 2018
  • Doi Number: 10.4183/aeb.2018.113
  • Journal Name: Acta Endocrinologica
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.113-116
  • Keywords: Cabergoline, Cystic macroprolactinoma, Pituitary apoplexy
  • Kütahya Health Sciences University Affiliated: No

Abstract

© 2018, Acta Endocrinologica Foundation. All rights reserved.Pituitary apoplexy (PA) is a life-threatening clinical syndrome. Dopamine receptor agonists are the drugs of choice in the treatment of prolactinomas. The use of cabergoline is reported to cause an increased risk of PA, particularly in macroprolactinomas of cystic nature. In this report, we present a patient with a cystic macroprolactinoma who developed PA on the 16th week of cabergoline treatment.